Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9563799 | 0.86 | LMNA (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL11018791 | 0.85 | LMNA (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL9189736 | 0.83 | LMNA (0.41) | LMNASMN1; SMN2 | |
| SCHEMBL9009268 | 0.82 | LMNA (0.36) | LMNA | |
| Iosimide SCHEMBL8845588 | 0.82 | CA2 (0.33) | — | |
| Iosimide SCHEMBL898150 | 0.82 | CA2 (0.33) | — | |
| SCHEMBL11020708 | 0.81 | LMNA (0.41) | LMNASMN1; SMN2 | |
| SCHEMBL11023150 | 0.80 | LMNA (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL7534673 | 0.79 | LMNA (0.51) | LMNASMN1; SMN2 | |
| SCHEMBL10455405 | 0.76 | LMNA (0.40) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8535642-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-09-17 | — | — | US | disclosed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | disclosed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | disclosed |
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | LMNA 1863/4885SMN1; SMN2 3850/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | LMNA 1863/4885SMN1; SMN2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.